For the millions who rely on antidepressants to navigate the weight of depression, a new question has long lingered quietly beneath the surface: what do these medicines ask of the heart in return? A major meta-analysis published in the British Medical Journal examined ten antidepressants across 35 randomized trials, finding that while some drugs modestly alter the heart's electrical recharge interval, the true story lies not in the drug alone but in the person receiving it — their age, kidney function, weight, and potassium levels all shaping the cardiac outcome in ways that averages cannot ca
Antidepressant heart effects vary by patient profile, major trial analysis finds
The drug alone does not determine the risk. The patient's body does.
Mark
So the headline is that amitriptyline and escitalopram lengthen the QTc interval. How worried should someone on those drugs be?
Mimi
The average increase is small—5 to 9 milliseconds. For most people, that's not a problem. But the study found that effects vary a lot depending on who you are. Age, kidney function, potassium level, body weight—all of those change the picture.
Luke
And how many people in the trials actually had a clinically significant QTc change? The study mentions some modeled profiles exceeded 30 milliseconds, but what's the actual count?
Mimi
That's where it gets limited. Only seven people had a QTc above 500 milliseconds, and 56 had increases above 60 milliseconds. The numbers are too small to draw firm conclusions about real risk.
Mark
Did anyone actually get sick from this? Any arrhythmias?
Mimi
No one in the individual participant data had torsade de pointes or sudden death. Ten people fainted. In the larger aggregate data, there were twelve sudden non-suicidal deaths total, but the rate was nearly identical between the antidepressant and placebo groups.
Luke
But here's the thing—these trials lasted weeks, not years. And the people in them were probably healthier than the people taking these drugs in real life. Someone with kidney disease or low potassium or who's also on another QT-prolonging drug might have a different experience entirely.
Mimi
Exactly. The researchers said the same thing. They called for real-world data to fill those gaps.
Mark
So what should a patient do if they're on escitalopram or amitriptyline?
Mimi
Talk to their doctor about their individual risk factors. If you're older, or your kidneys aren't working well, or your potassium is low, that changes the calculation. It's not a yes-or-no question about the drug. It's about whether it's the right drug for you.
Luke
And if someone's already on one of these drugs and doing fine? There's no signal here that they should stop.
Mimi
Right. The trials didn't find evidence of increased cardiovascular events. The concern is real but appears to be rare, and for many people the benefit of treating depression outweighs the risk.
El Pulso
- Amitriptyline and escitalopram produced measurable increases in the QTc interval — the heart's electrical recharge window — with escitalopram affecting 94% of modeled patient profiles, raising quiet concern among cardiologists and prescribers.
- Some individual patients showed QTc changes exceeding 30 milliseconds, a threshold European regulators flag as potentially clinically significant, meaning the average figures obscure real pockets of elevated risk.
- Age, kidney function, potassium levels, and BMI all dramatically shifted how each drug behaved — a 25-year-old and a 65-year-old on the same medication could experience meaningfully different cardiac effects.
- No cases of the dangerous arrhythmia torsade de pointes were recorded, and sudden death rates between antidepressant and placebo groups were nearly identical — but trials were too short and too small to detect rare or delayed harms.
- Researchers are now calling for real-world clinical data to fill the gaps these controlled trials cannot reach, particularly for patients with heart disease, electrolyte imbalances, or complex medication regimens.
For the millions who rely on antidepressants to navigate the weight of depression, a new question has long lingered quietly beneath the surface: what do these medicines ask of the heart in return? A major meta-analysis published in the British Medical Journal examined ten antidepressants across 35 randomized trials, finding that while some drugs modestly alter the heart's electrical recharge interval, the true story lies not in the drug alone but in the person receiving it — their age, kidney function, weight, and potassium levels all shaping the cardiac outcome in ways that averages cannot capture. The research does not counsel fear, but rather precision: the right antidepressant, for the right patient, chosen with the full human being in view.
In England alone, nearly nine million people filled antidepressant prescriptions over the past two years, and worldwide the numbers continue to rise. Yet a persistent question has shadowed this widespread use: do these mood-lifting drugs disturb the heart's electrical rhythm in ways that matter?
A major analysis in the British Medical Journal attempted to answer that question with unusual granularity. Researchers pooled data from 35 randomized trials and 8,679 participants, tracking changes in the QTc interval — a measure of how long the heart's ventricles take to recharge between beats. Prolongation of this interval can, in rare cases, trigger dangerous arrhythmias. Ten antidepressants were examined, alongside five patient characteristics: age, baseline QTc, potassium level, BMI, and kidney function.
The findings were neither alarming nor fully reassuring. Amitriptyline and escitalopram produced small average QTc increases of 5.3 and 8.7 milliseconds respectively, while mirtazapine actually shortened the interval slightly. But averages concealed important variation. When researchers modeled the same drugs across 216 different patient profiles, escitalopram increased QTc in 94 percent of combinations and amitriptyline in 85.7 percent — and some patients showed changes exceeding the 30-millisecond threshold European regulators consider potentially significant.
Age shaped outcomes in unexpected ways: mirtazapine and amitriptyline prolonged QTc more in younger patients, while fluoxetine and escitalopram did so more in older ones. Kidney function, potassium, and body weight all added further complexity. The message was clear — the drug alone does not determine the risk. The patient's body does.
When researchers searched for actual harm, they found little within these trials. No one experienced torsade de pointes, and the difference in sudden non-suicidal deaths between antidepressant and placebo groups amounted to just 0.01 percent. But the authors were candid about what the trials could not show: they were too short and too small to detect rare or delayed complications, and their participants were healthier than typical real-world patients who often carry additional medications and conditions that amplify cardiac risk.
The conclusion was not a warning against antidepressants — depression itself carries cardiovascular consequences. It was a call for precision: matching the drug to the full human being, and building the real-world evidence needed to close the gaps these trials leave behind.
In England alone, nearly nine million people filled antidepressant prescriptions during 2024 and 2025. Worldwide, the numbers keep climbing. But a question has shadowed this widespread use: do these drugs that lift mood also disturb the heart's electrical rhythm in ways that matter?
A major analysis published in the British Medical Journal set out to answer that question with unusual precision. Researchers gathered data from 35 randomized trials involving 8,679 participants, tracking changes in a heart measurement called the QTc interval—a marker of how long it takes the heart's ventricles to recharge between beats. Prolongation of this interval can signal an electrical instability that, in rare cases, leads to dangerous arrhythmias. The researchers examined ten antidepressants: amitriptyline, bupropion, duloxetine, escitalopram, fluoxetine, mirtazapine, paroxetine, trazodone, venlafaxine, and vortioxetine. They also looked at how five patient characteristics—age, baseline QTc length, potassium level, body mass index, and kidney function—shaped each drug's effect.
The findings were neither reassuring nor alarming, but rather granular. When researchers adjusted for patient characteristics, amitriptyline and escitalopram produced small average increases in QTc: 5.3 and 8.7 milliseconds respectively. Other drugs showed smaller changes or none at all. Mirtazapine, by contrast, actually shortened the QTc interval slightly. But these averages masked important variation. When researchers modeled how the same drug would affect different patient profiles—varying age, sex, baseline QTc, body weight, and potassium—the picture became more complex. Escitalopram increased QTc in 94 percent of the 216 modeled patient combinations tested. Amitriptyline did so in 85.7 percent. Yet some patients on these drugs showed changes exceeding 30 milliseconds, a threshold the European Medicines Agency considers potentially clinically significant.
Age mattered in unexpected ways. Mirtazapine and amitriptyline significantly prolonged QTc in younger patients, while fluoxetine and escitalopram did so more often in older ones. A 25-year-old and a 65-year-old taking the same drug could experience different cardiac effects. Kidney function, potassium levels, and body mass index all shaped the outcome as well. The message was clear: the drug alone does not determine the risk. The patient's body does.
Yet when researchers looked for actual harm, they found little evidence of it in these trials. Across the individual participant data, no one experienced torsade de pointes—the dangerous arrhythmia that QTc prolongation can herald. Ten people had fainting episodes. In a larger aggregate analysis of 139 trials involving 52,398 participants, twelve sudden non-suicidal deaths occurred: nine among those taking antidepressants, three among those on placebo. The risk difference was negligible—0.01 percent, with a confidence interval spanning from minus 0.01 to plus 0.02 percent.
But the researchers were careful to name what these trials could not show. The studies were not large enough or long enough to detect rare events or complications that emerge months or years after treatment begins. Trial participants tend to be healthier and less complicated than people in routine clinical care. The escitalopram analysis, in particular, drew data from only 186 participants. Real-world patients often take multiple medications, some of which also prolong QTc, or have conditions like heart disease or electrolyte imbalances that amplify risk. The trials simply could not capture that complexity.
The authors concluded that individual risk assessment matters. Age, kidney function, baseline heart rhythm, potassium, and weight should all factor into which antidepressant a doctor prescribes and whether it is the right choice for a particular person. The findings do not argue against antidepressants—depression itself carries cardiovascular risk. Rather, they argue for precision: matching the drug to the patient, not the patient to the drug. What happens next depends on whether clinicians and patients use this information to make more careful choices, and whether real-world data from actual clinical practice can fill the gaps these trials leave behind.
Citas Notables
The findings support considering individual risk factors during treatment selection and shared decision-making.— Study authors, British Medical Journal
Real-world data are needed to define these risks more precisely, particularly in patients with comorbidities or concurrent QT-prolonging medications.— Study authors
Quieres la nota completa?
Lee el original en news-medical.net ↗